Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer

RecruitingOBSERVATIONAL
Enrollment

286

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2027

Conditions
Breast Cancer
Interventions
DRUG

Ribociclib

Participants will receive ribociclib (at a dose of 400mg per day for 3 weeks, followed by 1 week off, 4 weeks for 1 cycle) plus physician-selected endocrine therapy (according to standard clinical practice, TAM or AI, with or without OFS).

Trial Locations (1)

310009

RECRUITING

Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
collaborator

The First Affiliated Hospital of Bengbu Medical University

OTHER

collaborator

Jinhua Central Hospital

OTHER

collaborator

Taizhou Central Hospital affiliated to Taizhou University

UNKNOWN

collaborator

Ningbo Medical Center Lihuili Hospital

OTHER_GOV

collaborator

The Affiliated People's Hospital of Ningbo University

OTHER_GOV

collaborator

The First Affiliated Hospital of Zhejiang Chinese Medical University

OTHER

collaborator

First People's Hospital of Hangzhou

OTHER

collaborator

Taizhou Hospital

OTHER

collaborator

Affiliated Zhoushan Hospital of Wenzhou Medical University

OTHER

collaborator

Zhejiang University

OTHER

collaborator

Sir Run Run Shaw Hospital

OTHER

collaborator

Women's Hospital School Of Medicine Zhejiang University

OTHER

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER